About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Target for New Rx Class for Inflammatory Disorders Discovered By LSUHSC Researcher

by Rukmani Krishna on October 8, 2013 at 12:08 AM
Font : A-A+

 Target for New Rx Class for Inflammatory Disorders Discovered By LSUHSC Researcher

A powerful new anti-inflammatory mechanism that could lead to the development of new oral medications for atherosclerosis and inflammatory bowel disorders (IBS) was described by new research. The research was led by Charles Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans. The findings are published in PLOS ONE, available online at http://dx.plos.org/10.1371/journal.pone.0075426.

Advertisement

One of the master inflammatory molecules in the body is Tumor Necrosis Factor-alpha (TNF-alpha). Infections and certain diseases lead to the production of this molecule, which then stimulates an immune response. Diseases like atherosclerosis, rheumatoid arthritis, and IBS are believed to have inflammation influenced by TNF-alpha as a primary component. Unfortunately, there are no convenient therapeutics to treat inflammation caused by TNF-alpha. Current therapies directed at blocking TNF-alpha inflammation are very expensive antibody treatments that are administered in the clinic. The research team found that activation of serotonin 5-HT2A receptor proteins potently blocks TNF-alpha induced inflammation. The serotonin 5-HT2A receptor is the main target of classic hallucinogenic drugs like LSD, and the drug the researchers used to activate the receptor protein is itself a member of this class.

In the study, the researchers activated serotonin 5-HT2A receptors, and then administered TNF-alpha to mice to produce an inflammatory response. In mice when 5-HT2A receptors were activated before TNF-alpha was administered, there was a near complete blockade of inflammation compared to mice where the 5-HT2A receptors were not activated that had a full inflammatory response. The effects were most powerful in vascular tissues like the aorta, and the intestine. In the intestine, inflammation was blocked with an extremely low dose of the drug - 300 times lower than required for any behavioral effects of the drug.
Advertisement

"Our results potentially represent a breakthrough of a new first in class orally available small molecule-based therapeutic strategy to treat inflammatory diseases involving TNF-alpha," notes Charles Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans. "Although the serotonin 5-HT2A receptor is the primary target for certain drugs, including LSD, to mediate their behavioral effects, the dose of drug necessary for anti-inflammatory effects is orders of magnitude lower than intoxicating doses, and future therapies may target directly the relevant cellular processes activated by the 5-HT2A receptor rather than the receptor itself."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Top 9 Reasons Why We Should Practice Kindness
Top 10 Vitamin B12 Foods for Vegetarians - Slideshow
Targeted Screening Program Beneficial for Prostate Cancer Screening
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Behcet's Syndrome Loss of Taste Uveitis 

Most Popular on Medindia

Loram (2 mg) (Lorazepam) Nutam (400mg) (Piracetam) Pregnancy Confirmation Calculator Find a Hospital Accident and Trauma Care Color Blindness Calculator Blood Pressure Calculator Drug Interaction Checker Sanatogen Iron Intake Calculator

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use